<DOC>
	<DOCNO>NCT00362466</DOCNO>
	<brief_summary>The purpose clinical research study compare rate complete cytogenetic response dasatinib imatinib therapy 6 month randomization chronic phase CML patient . The safety treatment also study .</brief_summary>
	<brief_title>A Study Dasatinib vs. High-Dose Imatinib ( 600 mg ) Patients With Chronic Phase Chronic Myeloid Leukemia ( CML ) Who Failed Achieve Complete Cytogenetic Response After 3-18 Months Imatinib Therapy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Men woman ≥18 year diagnose Chronic Phase Philadelphia chromosome positive ( CP Ph+ ) CML fail achieve CCyR 318 month therapy imatinib 400 mg Treatment initiation imatinib 400 mg within 6 month initial CML diagnosis Able tolerate chronic administration imatinib high dose ( 400600 mg ) subject receive past Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 02 Adequate hepatic renal function Eligible willing undergo immediate autologous/allogeneic stem cell transplant Previous diagnosis accelerated/blast crisis CML Subjects clonal evolution Ph+ cell observe ≥2 metaphase Previous documentation T315I mutation Uncontrolled significant cardiovascular disease Serious uncontrolled medical disorder/active infection History significant bleeding disorder unrelated CML Intolerance imatinib ≥400 mg Concurrent malignancy CML</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Leukemia ( chronic myeloid leukemia - chronic phase )</keyword>
</DOC>